The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Open accessAbstract
Importance: Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition. Objective: To determine the association between the use, the type of, and the timing of DMTs with the risk of conversion to secondary progressive MS diagnosed with a validated definition. Design, Setting, and Participants: Cohort study with prospective data from 68 neurology centers in 21 countries examining patients with relapsing-remitting MS commencing DMTs (or clinical monitoring) between 1988-2012 with minimum 4 years' follow-up. Exposures: The use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, natalizumab, or alemtuzumab. After propensity-score matching, 1555 patients were included (last follow-up, February 14, 2017). Main Outcome and Measure: Conversion to objectively defined secondary progressive MS. Results: Of the 1555 patients, 1123 were female (mean baseline age, 35 years [SD, 10]). Patients initially treated with glatiramer acetate or interferon beta had a lower hazard of conversion to secondary progressive MS than matched untreated patients (HR, 0.71; 95% CI, 0.61-0.81; P < .001; 5-year absolute risk, 12% [49 of 407] vs 27% [58 of 213]; median follow-up, 7.6 years [IQR, 5.8-9.6]), as did fingolimod (HR, 0.37; 95% CI, 0.22-0.62; P < .001; 5-year absolute risk, 7% [6 of 85] vs 32% [56 of 174]; median follow-up, 4.5 years [IQR, 4.3-5.1]); natalizumab (HR, 0.61; 95% CI, 0.43-0.86; P = .005; 5-year absolute risk, 19% [16 of 82] vs 38% [62 of 164]; median follow-up, 4.9 years [IQR, 4.4-5.8]); and alemtuzumab (HR, 0.52; 95% CI, 0.32-0.85; P = .009; 5-year absolute risk, 10% [4 of 44] vs 25% [23 of 92]; median follow-up, 7.4 years [IQR, 6.0-8.6]). Initial treatment with fingolimod, alemtuzumab, or natalizumab was associated with a lower risk of conversion than initial treatment with glatiramer acetate or interferon beta (HR, 0.66; 95% CI, 0.44-0.99; P = .046); 5-year absolute risk, 7% [16 of 235] vs 12% [46 of 380]; median follow-up, 5.8 years [IQR, 4.7-8.0]). The probability of conversion was lower when glatiramer acetate or interferon beta was started within 5 years of disease onset vs later (HR, 0.77; 95% CI, 0.61-0.98; P = .03; 5-year absolute risk, 3% [4 of 120] vs 6% [2 of 38]; median follow-up, 13.4 years [IQR, 11-18.1]). When glatiramer acetate or interferon beta were escalated to fingolimod, alemtuzumab, or natalizumab within 5 years vs later, the HR was 0.76 (95% CI, 0.66-0.88; P < .001; 5-year absolute risk, 8% [25 of 307] vs 14% [46 of 331], median follow-up, 5.3 years [IQR], 4.6-6.1). Conclusions and Relevance: Among patients with relapsing-remitting MS, initial treatment with fingolimod, alemtuzumab, or natalizumab was associated with a lower risk of conversion to secondary progressive MS vs initial treatment with glatiramer acetate or interferon beta. These findings, considered along with these therapies' risks, may help inform decisions about DMT selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference
Ho, D. E., Imai, K., King, G., & Stuart, E. A. (2007) · Political Analysis · doi:10.1093/pan/mpl013 · Cited by 4,205
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationCausal effects in nonexperimental studies: Reevaluating the evaluation of training programs
Dehejia, R. H., & Wahba, S. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10473858 · Cited by 2,395
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Self-citationThe IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,967
Immortal Time Bias in Pharmacoepidemiology
Suissa, S. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm324 · Cited by 1,708
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Self-citationAlemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Meyer-Moock, S., Feng, Y.-S., Maeurer, M., Dippel, F.-W., & Kohlmann, T. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-58 · Cited by 639
(2006) · Annals of Neurology · doi:10.1002/(issn)1531-8249 · Cited by 513
One‐to‐many propensity score matching in cohort studies
Rassen, J. A., Shelat, A. A., Myers, J., Glynn, R. J., Rothman, K. J., & Schneeweiss, S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3263 · Cited by 510
Chi-squared goodness-of-fit tests for the proportional hazards regression model
SCHOENFELD, D. (1980) · Biometrika · doi:10.1093/biomet/67.1.145 · Cited by 489
Defining secondary progressive multiple sclerosis
Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2016) · Brain · doi:10.1093/brain/aww173 · Cited by 415
Self-citationLunt, M. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwt212 · Cited by 358
Austin, P. C., & Stuart, E. A. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280215584401 · Cited by 316
New natural history of interferon‐β–treated relapsing multiple sclerosis
Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zipoli, V., Zimatore, G. B., Di Monte, E., Portaccio, E., Lepore, V., Livrea, P., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21102 · Cited by 270
Self-citationButzkueven, H., Chapman, J., Cristiano, E., Grand’Maison, F., Hoffmann, M., Izquierdo, G., Jolley, D., Kappos, L., Leist, T., Pöhlau, D., et al. (2006) · Multiple Sclerosis Journal · doi:10.1177/1352458506070775 · Cited by 245
Self-citationTreatment Optimization in MS: Canadian MS Working Group Updated Recommendations
Freedman, M. S., Selchen, D., Arnold, D. L., Prat, A., Banwell, B., Yeung, M., Morgenthau, D., & Lapierre, Y. (2013) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100014244 · Cited by 202
Self-citationLong term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
Hill-Cawthorne, G. A., Button, T., Tuohy, O., Jones, J. L., May, K., Somerfield, J., Green, A., Giovannoni, G., Compston, D. A. S., Fahey, M. T., et al. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-300826 · Cited by 193
Self-citationKalincik, T., Brown, J. W. L., Robertson, N., Willis, M., Scolding, N., Rice, C. M., Wilkins, A., Pearson, O., Ziemssen, T., Hutchinson, M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30007-8 · Cited by 164
Self-citationEbers, G. C., Traboulsee, A. L., Li, D., Langdon, D. W., Reder, A. T., Goodin, D. S., Bogumil, T., Beckmann, K., Wolf, C., Konieczny, A., et al. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.204123 · Cited by 123
He, A. H., Spelman, T. D., Jokubaitis, V., Havrdová, E., Horáková, D., Trojano, M., Lugaresi, A., Izquierdo, G., Grammond, P., Duquette, P., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4147 · Cited by 116
Self-citationWill Rogers phenomenon in multiple sclerosis
Sormani, M. P., Tintorè, M., Rovaris, M., Rovira, A., Vidal, X., Bruzzi, P., Filippi, M., & Montalban, X. (2008) · Annals of Neurology · doi:10.1002/ana.21464 · Cited by 104
Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort
Willis, M., Harding, K. E., Pickersgill, T. P., Wardle, M., Pearson, O. R., Scolding, N. J., Smee, J., & Robertson, N. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515614092 · Cited by 103
Self-citationThe prevalence of multiple sclerosis in south east Wales.
Swingler, R. J., & Compston, D. A. S. (1988) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.12.1520 · Cited by 92
Tedeholm, H., Lycke, J., Skoog, B., Lisovskaja, V., Hillert, J. A., Dahle, C., Fagius, J., Fredrikson, S., Landtblom, A., Malmeström, C., et al. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512463764 · Cited by 92
Immunomodulatory therapies delay disease progression in multiple sclerosis
Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., D’Onghia, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458512445941 · Cited by 71
Self-citationGoodin, D. S., Jones, J. P., Li, D., Traboulsee, A. L., Reder, A. T., Beckmann, K., Konieczny, A., Knappertz, V. A., & and the 16-Year Long-Term Follow-up Study Investigators (2011) · PLoS ONE · doi:10.1371/journal.pone.0022444 · Cited by 44
Self-citationSignori, A., Gallo, F., Bovis, F., Tullio, N. D., Maietta, I., & Sormani, M. P. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.01.007 · Cited by 43
Validity of patient-derived disability and clinical data in multiple sclerosis
Ingram, G., Colley, E., Ben‐Shlomo, Y., Cossburn, M., Hirst, C. L., Pickersgill, T., & Robertson, N. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509358902 · Cited by 41
Self-citationBeta‐interferon exposure and onset of secondary progressive multiple sclerosis
Zhang, T., Shirani, A., Zhao, Y., Karim, M. E., Gustafson, P., Petkau, J., Evans, C. D., Kingwell, E., van der Kop, M., Zhu, F., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12698 · Cited by 41
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS
Spelman, T. D., Kalinčík, T., Jokubaitis, V., Zhang, A., Pellegrini, F., Wiendl, H., Belachew, S. M., Hyde, R., Verheul, F., Lugaresi, A., et al. (2016) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000000227 · Cited by 37
Self-citationInterferon-beta and disability progression in relapsing-remitting multiple sclerosis
Drulovic, J. S., Kostić, J., Mesaroš, Š., Dujmović, I., Stojsavljević, N., Kisić-Tepavčević, D., & Pekmezovic, T. D. (2013) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2013.09.024 · Cited by 25
Cited by
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Kappos, L., Fox, R. J., Burcklen, M., Freedman, M. S., Havrdová, E. K., Hennessy, B., Hohlfeld, R., Lublin, F., Montalban, X., Pozzilli, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.0405 · Cited by 228
Metadata
- Authors
- Brown, J. W. L., Coles, A., Horakova, D., Havrdova, E., Izquierdo, G., Prat, A., Girard, M., Duquette, P., Trojano, M., Lugaresi, A., Bergamaschi, R., Grammond, P., Alroughani, R., Hupperts, R., McCombe, P., Van Pesch, V., Sola, P., Ferraro, D., Grand'Maison, F., Terzi, M., Lechner-Scott, J., Flechter, S., Slee, M., Shaygannejad, V., Pucci, E., Granella, F., Jokubaitis, V., Willis, M., Rice, C., Scolding, N., Wilkins, A., Pearson, O. R., Ziemssen, T., Hutchinson, M., Harding, K., Jones, J., McGuigan, C., Butzkueven, H., Kalincik, T., Robertson, N., & for the MSBase Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-01-15
- Volume
- 321
- Issue
- 2
- Pages
- 175
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2910867209
- Cited by
- 546
- References
- 41
- FWCI
- 41.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.